Participated · Equity · Jun 2026

Oversonic Robotics is a 2020-founded Italian deep tech firm focused on cognitive computing and humanoid robotics, headquartered in Carate Brianza with a team of 65 professionals. Its flagship platform, RoBee, is described as the first certified cognitive humanoid robot designed to operate in complex industrial environments and in healthcare settings. RoBee is already operating in manufacturing applications and is being developed for potential healthcare uses including assistance, logistics and operator support. The company positions RoBee as a platform to interact with people, machinery and environments via artificial intelligence. With the new capital and industrial partners, Oversonic plans to accelerate technological development, industrialization and international expansion, targeting broader deployments in Europe and the United States. The articles do not disclose revenue or user metrics.

Led · Series A · Jun 2026

Quobly develops silicon-based quantum processors and system-level architectures using FD-SOI technology on 300 mm wafers to enable semiconductor-grade manufacturability and dense integration. Its Alloy product line includes Alloy Pioneer, intended for early adopters in high-performance computing and research, and will be accessible through the cloud in 2026 with deployment into HPC environments planned for 2027. Quobly pairs hardware, control electronics and a software stack including Alloy Forge, its quantum application development environment, to allow developers to build and validate applications under realistic hardware constraints. The company emphasizes industrialization through partnerships with semiconductor and industrial leaders such as STMicroelectronics, Air Liquide, Soitec and Orano. Financially, Quobly completed a €19 million seed phase from 2023–2025 and has now raised a €115 million Series A to fund R&D, scaling of silicon quantum processors and commercial expansion. Its strategy centers on transferring quantum technologies into advanced manufacturing environments to address scalability, yield and reproducibility.

Participated · Series A · Jun 2016

Biovotion provides clinical-grade wearable solutions based on the company’s IP and know-how in non-invasive physiological monitoring, including vital sign, hydration, and glucose tracking. Its platform targets consumers and clinical users to support healthy lifestyles, improve healthcare treatment outcomes, and help reduce healthcare costs. The company says its offerings are grounded in clinical-grade measurement capabilities. Biovotion plans to use new funding to prepare the introduction of its platform into medical markets. The company was founded in 2011 by Dr. Andreas Caduff and is based in Zurich, Switzerland. Current financing activity indicates a push toward medical-market commercialization rather than a change in core product focus.